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Abstract- Dealing with radionuclides includes trapping the vapors and 
storing it for decay. However, these methods can involve considerable 
expense in infrastructure, manpower and monitoring. Legislation requires the 
presence of air filtration systems with detectors to monitor and control the 
release of radionuclides into the air in nuclear medicine centers.  We describe 
a method for the treatment of gaseous waste that is economically feasible and 
environmentally friendly. This method complies with legislation and has the 
advantage of using the already existing resources in the radiopharmaceutical 
production facility. 
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1. INTRODUCTION 
 
During radiochemical processing in nuclear medicine facilities, a substantial part of the 
positron-emitting radiopharmaceuticals is released into the environment (Mukherjee 
2002; Giardina et al. 2015). Council Directive 2013/59/Euratom requires the proper 
monitoring and evaluation of radioactive airborne material released in the environment 
and reporting of results to the competent authority in order to avoid the accidental release 
of high levels of radionuclides during the production of radiopharmaceuticals. In 
particular, Article 35 states that all Member States shall ensure that an adequate program 
is in place to monitor the level of radioactivity in the environment. In addition, Article 36 
stipulates that Members shall communicate the results of such monitoring to the 
Commission.  
Traditional methods of treating gaseous wastes with above-legal toxicity levels include 
waste gas release incorporating buffer tanks (Oehninger and Weinreich 1994), automated 
waste gas compression systems (Pascali et al. 1996) and compression systems 
(Calandrino et al. 2007). If the level of toxicity is higher than allowed by law, toxic 
radionuclides are diverted to a place where they will decay.1 
Although most commercially available hot cells and automated synthesis modules have 
capture devices, such as activated carbon filters, chemical adsorbents and liquid nitrogen 
traps (Calandrino et al. 2007), not all the radioactive gases and aerosols created are 
effectively trapped. Therefore, these gas compression storage systems need additional 
protection; otherwise, the by-products generated in the process are dumped directly into 
the atmosphere. We present a method to obviate these problems as well as being effective 
for the treatment of these radioactive gases and residues, for a biomedical research center, 
focusing on conventional nuclear medicine and positron emission tomography (PET). 
 
 
2. LEGISLATION 
 
The regulatory system. At the international level, there is an obligation to establish a 
regulatory mechanism. In some countries, a Regulatory Authority has been created 
consisting of a single entity specifically dedicated to radiological protection. 
In Portugal, the respective competencies are assigned to a set of existing entities, of 
which: the Directorate General of Health (DGS); Regional Health Administrations 
(ARS); Technological and Nuclear Institute (ITN); the Portuguese Environment Agency 
(APA); Directorate General of Energy and Geology (DGEG); the Regional Directorates 
of the Economy (DRE). The specific competences of each entity, with regard to 
radiological protection, are defined in Decree-Law no. 165/2002. Later, Decree-Law no. 
139/2005, as an independent supervisor of the entire system, created the Independent 
Commission for Radiological Protection and Nuclear Safety. This Commission, 
composed of elements directly appointed by the Prime Minister, has among its powers 
the capacity to propose amendments and recommendations to the other authorities 
involved. Despite the existence of a large number of radiological installations for medical 
and industrial purposes, the only nuclear installation in Portugal for research and teaching 
purposes, is the Portuguese Research Reactor (RPI) operated by the Technological and 
Nuclear Institute.  
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Radiation protection activities in the Directorate General for Health are assigned to the 
Environmental and Occupational Health Division of the Directorate for Health Promotion 
and Protection Services. However, the Guidelines for the Management of Radioactive 
Waste in Portugal suggest that it is technically acceptable that the effluent discharge 
contains small volumes of radioactive material in a controlled manner in certain 
situations, as the most reasonable option in the case of very short-lived waste (VSLW) in 
situations duly provided for by law or authorized by the authority (Sampaio and Fonseca 
2015, p. 8). 
 
3. PRODUCTION OF RADIONUCLIDES 
 
For the production, research and development of radiopharmaceuticals, the center has two 
radiopharmaceutical laboratories and a cyclotron, used in both diagnostic and therapy. In 
diagnostic, it produces radioactive isotopes typically used in PET treatments. 
Housed in the bunker, the Cyclone 18/9™ Cyclotron from IBA accelerates protons of up 
to 18 MeV and deuterium up to 9 MeV to produce radionuclides. These are transported 
to the radiopharmacy laboratory, where they are used in the synthesis of 
radiopharmaceuticals. Table 1 shows the levels of present and future nuclide production. 
 
 Table 1- Production levels, duration and activity 
Nuclides Present Future Duration Activity (UNITS) 
Production Frequency (times a week) (in minutes) Min. max 
18F 10-15 Slight decresase 60-120 250 740 
11C 10-12 same 20-30 37 74 
68Ga 2 10 30-60 3.7 14.8 
64Cu 1 2 480-720 2 7.4 
 
The main radioisotope currently produced is 18F in the synthesis of 
18Fluorodeoxyglucose (FDG), but other radioisotopes such as 11C, 68Ga and 64Cu are 
also produced. Table 2 shows the characteristics of the nuclides. 
 
Table 2- characteristics of the Nuclides 
Nuclide Half-life (minutes) Decay mode 
18F 109.8 β+ 
11C 20.4 SF 
68Ga 68 β+ 
64Cu 762 β+, β- 
 
 
Fluoride (F-18) is one of the most popular short-lived positron emission radioisotopes 
(T1/2 = 109.8 min) (Wilson et al. 2008). Its use as a radioactive marker in combination 
with noninvasive and metabolic PET imaging techniques is of great importance in 
medical imaging (Cai et al. 2008). In fact, FDG is the most successful and widely used 
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clinical imaging PET marker in oncology (Hoh 2007; Yu 2006). Thus, PET radioisotope 
production is well established and is routinely monitored for the generation of volatile 
radioactive gaseous and aerosol by-products, whose storage and disposal are challenging 
in financial and environmental terms (Pascali et al. 1996). 
Carbon-11, whose half-life is 20.334 min, is the most stable artificial radioactive isotope 
and is often used in the radioactive labeling of molecules in PET. Its decay occurs mainly 
due to the emission of positrons. 
Gallium-68 is a positron-emitting isotope with a half-life of 68 min, which is generated 
from germanium-68 for use in diagnostic tomography. It is normally attached as a label 
to a carrier molecule. 
Finally, copper-64 has a half-life of 762 min and is a positron emitter, making it a viable 
radionuclide for PET imaging. Thus, it can be used in cancer radiotherapy, medical 
research and diagnostic practice (Blower 2015). Its characteristics allow simultaneous 
monitoring of the distribution of drugs and bio-kinetics. 
Irradiation during 18FDG production is typically < 2 h, with varying downtime between 
the production cycles. For long-lived nuclides (T1/2 > 90 days), the waiting time between 
production cycles (typically < 3 days) is insignificant compared to half-life, and sample 
activity is relatively constant (less than 3%). For very short-lived nuclides (T1/2 < 15 
min), saturation activity is easily achieved within a single production line, but the nuclide 
also decays very rapidly. 
The radionuclides produced at the center are between these two limits (long- and very 
short-lived nuclides). In this case, a part of the product decays between the production 
cycles, accumulates during the next cycle and then decays further in a repetition cycle. 
Thus, the actual time needed to achieve saturation varies with the half-life and time 
intervals between production cycles. 
In Portugal, dose limits are regulated by Decree-Law no. 22/2008 of 17 November and 
are in conformity with the requirements of Council Directive 96/29/Euratom of 13 May, 
of which the effective dose limit for exposed workers is set at 100 mSv averaged over a 
period of five consecutive years, provided that it does not exceed a maximum effective 
dose of 50 mSv in each year. 
Notwithstanding this limit, the following are also fixed: The equivalent dose limit for the 
lens was set at 150 mSv per year but current regulations has reduced this limit to 20 mSv 
per year with significant impact on the monitoring and dose implications to the worker; 
the equivalent dose limit for the skin is set at 500 mSv per year; the equivalent dose limit 
for the purposes is set at 500 mSv per year. The effective dose limit for the public is set 
at 1 mSv per year and may be exceeded in a given year, if the average dose for five 
consecutive years does not exceed 1 mSv per year. 
 
Radiosynthesis equipment. Preventive maintenance and operational use of the Cyclone 
18/9™ Cyclotron from IBA used for the production of nuclides produce long-lived 
activated waste that must be classified by radionuclide and pre-disposal activity as LLRW 
(low-level radioactive waste). The cyclotron can generate large volumes of waste from 
the production of various positron emitters; however, full spectrometric gamma analysis 
of all wastes is expensive, and excessive waste handling is contrary to the ALARA 
concept (Breuning 2010). 
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It is the center’s responsibility and obligation to minimize gaseous radioactive waste 
using the most feasible means. Therefore, our goal is not to discard, but to safely retain 
as much radioactive waste as possible, which is created during any isotope production. 
In each of the two radiopharmacy laboratories, there are two armored COMERER™ cells 
that have their protection mechanisms. Indeed, the cells possess outer surface and internal 
work area of seamless stainless steel with rounded edges for easy decontamination. In 
addition, the safety locking system prevents its opening in the presence of greater activity 
within the limits predetermined by the user. Other characteristics of these cells include 
extraction of activated carbon filter and configurable ventilation system with pressure 
control under the cell and warning in case of pressure failure. The purity of the lead 
responsible for the radioprotection characteristics of these cells is 99.97%. Moreover, 
since the synthesis and fraction systems installed in armored cells are automated, 
exposure to radiation is minimized. As the cyclotron is not self-protected, it is placed in 
a bunker with walls made of two meters of concrete and a door equipped with an 
automatic control system for opening and closing. Before it is activated, people are 
evacuated from the sealed area. 
The bunker door fits into the walls and has safety mechanisms such as an audible alarm 
when it opens/closes slowly, stopping its movement when the sensors detect any 
impediment and cease immediately displacement in case of emergency. 
Since the synthesis and fraction systems installed in armored cells are automated, 
exposure to radiation is minimized. The cyclotron also has a safety key that needs to be 
placed in the control room in the ON position prior to the production of radionuclides. 
During cyclotron operation, neutron and gamma radiation levels are measured outside the 
bunker. The area dose rate monitoring system is located within the cyclotron. 
 
 
4. COST-EFFECTIVE ANALYSIS  OF GASEOUS WASTE MANAGEMENT 
 
Radiation is mainly the gamma resulting from the annihilation of positrons. Background 
radiation is measured when the cyclotron is not in operation. To this end, there is a neutron 
flux monitoring system located in the chamber that accesses the bunker: in the technical 
corridor (behind the bunker) and on the ground floor of the waiting room (because it is 
situated above the bunker). 
Figure 1 shows the blueprint of the center. The synthesis of FDG is produced in the 
radiopharmacy laboratory 1, whereas radiopharmacy laboratory 2, which is dedicated to 
research, receives the radioactive atoms of 11C, 13N and 15O produced in the cyclotron. 
The technical corridor links the cyclotron bunker (1) to the radiopharmacy laboratories 
(2 and 3). 
 
 
6 
 
 
 
Figure 1- Blueprint of Floor B2 
Legend 
1- Cyclotron Bunker 
2- Radiopharmacy Lab 1 
3- Radiopharmacy Lab 2 
4- Technical corridor  
 
Instead of being released into the atmosphere, the radionuclides with a level of toxicity 
above that allowed by law are transported through the technical corridor (4), from the 
radiopharmacy laboratories (2) and (3) to the cyclotron bunker (1). 
Figure 2 shows the interior of the bunker where the cyclotron is located.  
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Figure 2- Cyclotron bunker 
 
The insertion of the radioactivity is done in the northwest corner of the bunker along the 
ground. The air inside the bunker is exhausted through the ventilation system in the center 
of the ceiling. The principle of the radioactive management is the simple dispersion in the 
cyclotron bunker, which is particularly large (58.02 m2) when compared to other 
cyclotron bunkers. 
 
There are a number of problems related to protecting humans and the environment from 
exposure to radiation. First of all, and according to Wagner (2003), environmental law 
faces the major problem of lack of scientific information to assess the impact of industrial 
activities on public health and the environment. In the absence of such research, a number 
of authors (for example, Mukherjee 2002; Giardina et al. 2015; Infantino 2015; Ferdous 
et al. 2017) have focused on measuring the radiation level of their medical facilities and 
comparing it with the legal permitted levels. In addition, in Portugal, although there are 
more than 100 laws, regulations and decrees governing nuclear activities, the legal 
framework is incomplete (NEA 2011). Many PET plants simply discharge the waste 
through the ventilation system into the atmosphere or are equipped with devices such as 
gas compression systems to collect, transfer and store the waste tanks armored lead. 
However, these devices take up a lot of space (Won et al. 1997) and the costs of disposal 
have risen substantially as disposal facilities have developed. As a result, and as part of 
cost-reduction efforts, some countries show a trend to minimize the production of 
radioactive wastes (Rau et al. 2000). At the same time, less expensive solutions have been 
sought for disposal of VLLW. 
These solutions are basically two: buffer tanks or long pipes for delaying the expulsion 
of gases (Tochon-Danguy et al.1994; Pascali et al. 1996) and gas capture bags with 
electronic feedback that are integrated with the cyclotron safety system (Schweiger 2011; 
Stimson et al. 2016). Table 3 shows a comparison of costs between three methods: gas 
compression systems, gas capture bags and our method. 
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Table 3- Costs of gaseous waste disposal 
Gas compression systems Gas capture bags  Our method 
> USD $ 100,000 USD $20,000 USD $ 0 
Source: Own elaboration based on Stimson et al., 2016. 
 
Our new simple technique allows treating radioactive gases and aerosols generated during 
production without the need for additional space and it is less expensive than the other 
solutions. Thus, our method is practical, effective, reliable and cost-effective. 
 
Limitations. It may be noted that this method of waste disposal undermines the long-term 
profitability of cyclotron production. However, so far this argument has not been proven. 
 
 
5. CONCLUSION  
 
Compliance of levels of toxicity with legislation is checked on the battery monitor so that 
it never exceeds legal limits. Air dispersion immediately decreases the level of toxicity to 
legally accepted levels. The bunker is especially large (58.02 m2); therefore, future 
research would be checking if the dispersion of gaseous wastes in a bunker of smaller 
dimensions would immediately reduce activity to acceptable levels of toxicity, and to 
calculate the minimum closed area that allows the immediate dispersion of toxicity to 
levels below the legal limit. This method complies with the legislation and has the 
advantage of using the existing resources in the Nuclear Medicine Center. Therefore, this 
method is reliable and cheaper than traditional methods. 
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